This small-cap Pharma stock engaged in manufacturing and marketing of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished formulations, serving healthcare needs globally, jumped 3 percent after the company reported a March quarterly result, along with a 30 percent dividend, and announced a 1:1 bonus issue.
With a market capitalization of Rs. 1,044.84 crores, the share of Anuh Pharma Limited has reached an intraday high of Rs. 212.80 per equity share, rising nearly 2.75 percent from its previous day’s close price of Rs. 207.10. Since then, the stock has retreated and is currently trading at Rs. 208.50 per equity share.
Q4 FY25 Result Walkthrough:
Coming into the quarterly results of Anuh Pharma Limited, the company’s consolidated revenue from operations increased by 21.34 percent YOY, from Rs. 163.89 crore in Q4 FY24 to Rs. 198.14 crore in Q4 FY25, and grew by 24.22 percent QoQ from Rs. 159.51 crore in Q3 FY25.
Further, the company’s EBITDA has increased by 27.67 percent, from Rs. 15.72 crore in Q3 FY25 to Rs. 20.07 crore in Q4 FY25. In Q4 FY25, Anuh Pharma Limited’s consolidated net profit decreased by 18.83 percent YOY, reaching Rs. 12.46 crore compared to Rs. 15.35 crore during the same period last year. As compared to Q3 FY25, the net profit has increased by 20.50 percent, from Rs. 10.34 crore.
The basic earnings per share increased by 20.87 percent and stood at Rs. 2.49 as against Rs. 2.06 recorded in the previous quarter in the financial year 2025.
- Bonus Shares: The Board of Directors of Anuh Pharma Limited has approved issuing bonus shares in the ratio of 1:1, meaning shareholders will receive 1 fully paid-up equity share of Rs. 5 each for every 1 fully paid-up equity share held.
- Dividend: The Anuh Pharma board of directors has recommended paying a final dividend at the rate of 30 percent on the face value of paid-up equity shares of Rs. 5 each for the financial year 2024-25, which is a dividend of Rs. 1.50 per equity share.
- FY25 Result: Anuh Pharma Limited’s revenue has increased from Rs. 647 crore in FY24 to Rs. 661.51 crore in FY25, which is a growth of 2.24 percent. The net profit has decreased by 21.15 percent, from Rs. 60.05 crore in FY24 to Rs. 47.35 crore in FY25.
Anuh Pharma Limited was established in 1960 and is part of the SK Group. The company is a leading Indian manufacturer of bulk drugs and active pharmaceutical ingredients (APIs), with a production capacity of 2,200 metric tonnes per annum (MTPA).
The company is one of India’s largest manufacturers of macrolides and anti-TB products. The company is also a major player in anti-bacterials, anti-malarials, anti-hypertension, expectorants, and corticosteroid products.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
